Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Nov 16:16:100493.
doi: 10.1016/j.conctc.2019.100493. eCollection 2019 Dec.

Biomarker-guided trials: Challenges in practice

M Antoniou  1 , R Kolamunnage-Dona  1 , J Wason  2 , R Bathia  3 , C Billingham  4 , J M Bliss  5 , L C Brown  3 , A Gillman  5 , J Paul  6 , A L Jorgensen  1
Affiliations

Biomarker-guided trials: Challenges in practice

M Antoniou et al. Contemp Clin Trials Commun. .

Abstract

Biomarker-guided trials have drawn considerable attention as they promise to lead to improvements in the benefit-risk ratio of treatments and enhanced opportunities for drug development. A variety of such designs have been proposed in the literature, many of which have been adopted in practice. Implementing such trial designs in practice can be challenging, and identifying those challenges was the main objective of a workshop organised by the MRC Hubs for Trials Methodology Research Network's Stratified Medicine Working Group in March 2017. Participants reflected on completed and ongoing biomarker-guided trials to identify the practical challenges encountered. Here, the key challenges identified during the workshop including those related to funding, ethical and regulatory issues, recruitment, monitoring of samples and laboratories, biomarker assessment, and data sharing and resources, are discussed. Despite the complexities often associated with biomarker-guided trials, the workshop concluded that they can play an important role in advancing the field of personalised medicine. Therefore, it is important that the practical challenges surrounding their implementation are acknowledged and addressed.

Keywords: Biomarker; Challenges; Clinical trial; Personalised medicine.

PubMed Disclaimer

Conflict of interest statement

The authors do not have any competing interests to declare.

References

    1. Landeck L., Kneip C., Reischl J., Asadullah K. Biomarkers and personalized medicine: current status and further perspectives with special focus on dermatology. Exp. Dermatol. 2016;25(5):333–339. - PubMed
    1. Bailey A.M., Mao Y., Zeng J., Holla V., Johnson A., Brusco L. Implementation of biomarker-driven cancer therapy: existing tools and remaining gaps. Discov medicin. 2014;17(92):101–114. - PMC - PubMed
    1. Antoniou M., Jorgensen A.L., Kolamunnage-Dona R. Biomarker-guided adaptive trial designs in phase II and phase III: a methodological review. PLoS One. 2016;11(2) - PMC - PubMed
    1. Antoniou M., Kolamunnage-Dona R., Jorgensen A.L. Biomarker-guided non-adaptive trial designs in phase II and phase III: a methodological review. J. Personalized Med. 2017;7(1) - PMC - PubMed
    1. Freidlin B., Korn E.L. Biomarker-adaptive clinical trial designs. Pharmacogenomics. 2010;11(12):1679–1682. - PubMed

LinkOut - more resources